Cargando…

Clinical evaluation of commercial automated SARS-CoV-2 immunoassays

OBJECTIVE: Numerous immunoassays for detecting antibodies directed against SARS-CoV-2 have been rapidly developed and released. Validations of these have been performed with a limited number of samples. The lack of standardisation might lead to significantly different results. This study compared te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kittel, Maximilian, Muth, Maria Christina, Zahn, Ingrid, Roth, Heinz-Jürgen, Thiaucourt, Margot, Gerhards, Catharina, Haselmann, Verena, Neumaier, Michael, Findeisen, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725057/ https://www.ncbi.nlm.nih.gov/pubmed/33310108 http://dx.doi.org/10.1016/j.ijid.2020.12.003

Ejemplares similares

Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay
por: Kittel, Maximilian, et al.
Publicado: (2021)

Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples
por: Haselmann, Verena, et al.
Publicado: (2020)

Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines
por: Gerhards, Catharina, et al.
Publicado: (2023)

Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection
por: Gerhards, Catharina, et al.
Publicado: (2021)

Anosmia Testing as Early Detection of SARS-CoV-2 Positivity; A Prospective Study under Screening Conditions
por: Jungbauer, Frederic, et al.
Publicado: (2022)

Humoral SARS-CoV-2 Immune Response in COVID-19 Recovered Vaccinated and Unvaccinated Individuals Related to Post-COVID-Syndrome
por: Gerhards, Catharina, et al.
Publicado: (2023)

Assessing the Quality of Serological Testing in the COVID-19 Pandemic: Results of a European External Quality Assessment (EQA) Scheme for Anti-SARS-CoV-2 Antibody Detection
por: Ast, Volker, et al.
Publicado: (2021)

Triptychon: Usability evaluation and implementation of a web-based application for patients’ lab and vital parameters
por: Kittel, Maximilian, et al.
Publicado: (2023)

Exploring the Synergistic Potential of Radiomics and Laboratory Biomarkers for Enhanced Identification of Vulnerable COVID-19 Patients
por: Gerhards, Catharina, et al.
Publicado: (2023)

Results of a European-Wide External Quality Assessment (EQA) Scheme for Serological Detection of Anti-SARS-CoV-2 (CoVimm)—Pitfalls of Routine Application
por: Kittel, Maximilian, et al.
Publicado: (2022)

Plasma-based S100B testing for management of traumatic brain injury in emergency setting
por: Haselmann, Verena, et al.
Publicado: (2021)

Antibody Response to Vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms
por: Rotterdam, Jil, et al.
Publicado: (2021)

Liquid Profiling for Cancer Patient Stratification in Precision Medicine—Current Status and Challenges for Successful Implementation in Standard Care
por: Haselmann, Verena, et al.
Publicado: (2022)

Lupus Antibody Mimicking Reduced Plasmatic Coagulation in a Patient With Atrial Fibrillation and Ischemic Stroke
por: Huseynov, Aydin, et al.
Publicado: (2020)

A comparison of SARS-CoV-2 nucleocapsid and spike antibody detection using three commercially available automated immunoassays
por: Poore, Brad, et al.
Publicado: (2021)

Validation of a commercially available SARS-CoV-2 serological immunoassay
por: Meyer, B., et al.
Publicado: (2020)

Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays
por: Weidner, Lisa, et al.
Publicado: (2020)

Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population
por: Ige, Fehintola, et al.
Publicado: (2021)

Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2
por: Nilles, Eric J., et al.
Publicado: (2020)

Automated separation for heterogeneous immunoassays
por: Truchaud, A., et al.
Publicado: (1991)

Automated detection of neutralizing SARS-CoV-2 antibodies in minutes using a competitive chemiluminescence immunoassay
por: Klüpfel, Julia, et al.
Publicado: (2022)

Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay
por: Riester, Elena, et al.
Publicado: (2021)

Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases
por: Rotterdam, Jil, et al.
Publicado: (2022)

Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies
por: Lokida, Dewi, et al.
Publicado: (2022)

A comparison of 7 commercial anti-SARS-CoV-2 antibody immunoassays
por: Swadźba, Jakub, et al.
Publicado: (2020)

Specific requirements for automation of immunoassays in 1990
por: Haeckel, R.
Publicado: (1991)

Multicenter comparison of automated procalcitonin immunoassays
por: Dipalo, Mariella, et al.
Publicado: (2015)

Comparison of commercial lateral flow immunoassays and ELISA for SARS-CoV-2 antibody detection
por: Serrano, Maria Martínez, et al.
Publicado: (2020)

Evaluation of the SARS-CoV-2-IgG response in outpatients by five commercial immunoassays
por: Wellinghausen, Nele, et al.
Publicado: (2020)

Evaluation of 5 Commercially Available Zika Virus Immunoassays
por: Safronetz, David, et al.
Publicado: (2017)

SARS-CoV-2 antibody testing—questions to be asked
por: Özçürümez, Mustafa K., et al.
Publicado: (2020)

Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
por: Santano, Rebeca, et al.
Publicado: (2021)

Do fully automated immunoassays for the evaluation of the immune response to SARS-CoV-2 are commutable?
por: Mairesse, A., et al.
Publicado: (2021)

The Detection of SARS-CoV2 Antigen in Wastewater Using an Automated Chemiluminescence Enzyme Immunoassay
por: Thongpradit, Supranee, et al.
Publicado: (2022)

Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern
por: Osterman, Andreas, et al.
Publicado: (2021)

First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
por: Boulo, Sébastien, et al.
Publicado: (2020)

Clinical evaluation of four commercial immunoassays for the detection of antibodies against established SARS-CoV-2 infection
por: Chua, Kyra Y.L., et al.
Publicado: (2020)

Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test
por: Šimánek, Václav, et al.
Publicado: (2021)

Multicenter Analytical Evaluation of the Automated Electrochemiluminescence Immunoassay for Cyclosporine
por: Vogeser, Michael, et al.
Publicado: (2014)

Pregnancy disrupts the accuracy of automated fT4 immunoassays
por: Jansen, Heleen I, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1emokc15lsrjt6bf3au4q3v97q